
MPLT Stock Forecast & Price Target
MPLT Analyst Ratings
Bulls say
MapLight Therapeutics is a clinical-stage biopharmaceutical company with a promising discovery platform aiming to develop novel treatments for central nervous system disorders. Its lead candidate, ML-007C-MA, has shown potential in treating schizophrenia and Alzheimer's disease psychosis with reduced side effects. While there are competitive risks and uncertainties associated with trial outcomes, positive results could significantly impact the company's valuation.
Bears say
MapLight Therapeutics is currently in the clinical stage of drug development, and while its discovery platform shows potential for targeting specific neural circuits, the success of its product candidate, ML-007, is still uncertain in treating schizophrenia and ADP. Furthermore, with other potential treatments for these conditions also in development, MapLight faces competition in the market. Additionally, the article raises concerns about the company's ability to generate revenue, as it is currently focused on research rather than production. These factors combine to give a negative outlook on MapLight's stock.
This aggregate rating is based on analysts' research of MapLight Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MPLT Analyst Forecast & Price Prediction
Start investing in MPLT
Order type
Buy in
Order amount
Est. shares
0 shares